FBIO News and Press, Fortress Biotech Inc. From 09/27/23

2023-09-27 14:04:27 ET More on Fortress Biotech Stocks To Watch: Investors Prep For Inflation Data And Q2 Earnings Rush Journey Medical announces exclusive license agreement with Maruho Journey Medical stock rallies 20% on Phase 3 studies update Seeking Alpha...

WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a panel prese...

MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced...

WORCESTER, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers an...

2023-09-06 09:11:11 ET More on Journey Medical, Fortress Biotech Journey Medical Corporation ( DERM ) Q2 2023 Earnings Call Transcript Stocks To Watch: Investors Prep For Inflation Data And Q2 Earnings Rush Journey Medical stock rallies 20% on Phase 3 studies upd...

WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a corporate overview...

SCOTTSDALE, Ariz., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (&#...

MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced th...

Initial data show clinical responses from four of four indolent lymphoma patients, including complete response in follicular lymphoma patient previously treated with CD19 CAR-T cell therapy Aligns with ongoing results from investigator-sponsored trial at Fred Hutch that show ongoing c...

2023-08-14 17:02:56 ET Fortress Biotech press release ( NASDAQ: FBIO ): Q2 Non-GAAP EPS of -$0.07 misses by $0.13 . Revenue of $17.39M (-7.9% Y/Y) misses by $6.6M . For further details see: Fortress Biotech Non-GAAP EPS of -$0.07 misses by $0.13, revenue ...